{
  "ticker": "LLY",
  "target_date": "2024-12-20",
  "actual_date": "2024-12-20",
  "collected_at": "2025-12-08T11:10:36.183992",
  "price": {
    "open": 805.34,
    "high": 805.34,
    "low": 760.93,
    "close": 762.0758666992188,
    "volume": 9942300,
    "change_1d_pct": 1.35,
    "change_7d_pct": -3.55,
    "change_30d_pct": -3.56
  },
  "technicals": {
    "rsi_14": 37.51,
    "sma_20": 783.63,
    "sma_50": 814.94,
    "macd": -11.624,
    "macd_signal": -9.881,
    "macd_histogram": -1.743,
    "bb_upper": 830.67,
    "bb_lower": 736.59,
    "price_vs_sma20_pct": -2.75,
    "price_vs_sma50_pct": -6.49,
    "volume_ratio": 2.61
  },
  "fundamentals": {
    "market_cap": 890248822784,
    "pe_ratio": 48.656296,
    "forward_pe": 43.825024,
    "price_to_book": 37.389874,
    "price_to_sales": 14.98236,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.69,
    "pct_from_52w_low": 59.2
  },
  "macro": {
    "spy": {
      "price": 586.02,
      "change_1d_pct": 1.2,
      "change_7d_pct": -1.85
    },
    "vix": {
      "level": 18.36,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.52
    },
    "dollar_index": {
      "level": 107.62
    },
    "gold": {
      "price": 2628.7
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Novo Nordisk Stock Crashes on Obesity Drug Data. It\u2019s a Win for Eli Lilly.",
      "source": "Yahoo",
      "datetime": 1734704400,
      "summary": "For more than a year, Novo Nordisk has told the world it expects patients to lose \u201cat least 25%\u201d of their body weight on its experimental drug CagriSema.  On Friday, Novo released the results of a large Phase 3 trial of the drug.  Patients lost only 22.7% of their body weight, on average, after abou",
      "url": "https://finnhub.io/api/news?id=9c26b935da435aa9465533f649c0918091a9eff0390bc1357fdd44055de83e36"
    },
    {
      "headline": "Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?",
      "source": "Yahoo",
      "datetime": 1734735495,
      "summary": "Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.",
      "url": "https://finnhub.io/api/news?id=4cf84c3f876a5d6fa2670d1527b8a7fc38a198321a996917461fd441063f0142"
    },
    {
      "headline": "FDA approves Zepbound\u00ae (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity",
      "source": "Yahoo",
      "datetime": 1734730320,
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound\u00ae (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe o",
      "url": "https://finnhub.io/api/news?id=334bb356544192ce1f3a80d09cb1e85a292c01609d4dade2b507c41f779f5cbd"
    },
    {
      "headline": "Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.",
      "source": "Yahoo",
      "datetime": 1734719769,
      "summary": "Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.",
      "url": "https://finnhub.io/api/news?id=dc041da50e6e44284cc65bce2bc914dfd8fabf08d2b05a05c3ef84355fb1c036"
    },
    {
      "headline": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients",
      "source": "DowJones",
      "datetime": 1734725100,
      "summary": "Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients",
      "url": "https://finnhub.io/api/news?id=dfbde3d0b0979120b41aaa184c633336ac9b6a6ae7a9a1497604c8c7884ee2cc"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}